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Abstract
Background: Myosin performs ATP free energy transduction into mechanical work in the motor domain of the
myosin heavy chain (MHC). Energy transduction is the definitive systemic feature of the myosin motor performed
by coordinating in a time ordered sequence: ATP hydrolysis at the active site, actin affinity modulation at the actin
binding site, and the lever-arm rotation of the power stroke. These functions are carried out by several conserved
sub-domains within the motor domain. Single nucleotide polymorphisms (SNPs) affect the MHC sequence of many
isoforms expressed in striated muscle, smooth muscle, and non-muscle tissue. The purpose of this work is to
provide a rationale for using SNPs as a functional genomics tool to investigate structurefunction relationships in
myosin. In particular, to discover SNP distribution over the conserved sub-domains and surmise what it implies
about sub-domain stability and criticality in the energy transduction mechanism.
Results: An automated routine identifying human nonsynonymous SNP amino acid missense substitutions for any
MHC gene mined the NCBI SNP data base. The routine tested 22 MHC genes coding muscle and non-muscle
isoforms and identified 89 missense mutation positions in the motor domain with 10 already implicated in heart
disease and another 8 lacking sequence homology with a skeletal MHC isoform for which a crystallographic model
is available. The remaining 71 SNP substitutions were found to be distributed over MHC with 22 falling outside
identified functional sub-domains and 49 in or very near to myosin sub-domains assigned specific crucial functions
in energy transduction. The latter includes the active site, the actin binding site, the rigid lever-arm, and regions
facilitating their communication. Most MHC isoforms contained SNPs somewhere in the motor domain.
Conclusions: Several functional-crucial sub-domains are infiltrated by a large number of SNP substitution sites
suggesting these domains are engineered by evolution to be too-robust to be disturbed by otherwise intrusive
sequence changes. Two functional sub-domains are SNP-free or relatively SNP-deficient but contain many disease
implicated mutants. These sub-domains are apparently highly sensitive to any missense substitution suggesting
they have failed to evolve a robust sequence paradigm for performing their function.
Background
Single nucleotide polymorphisms (SNPs) are common
single base DNA sequence variants that account for a
sizable portion of the genetic variability between indivi-
duals. Some SNPs are common and have minor allele
frequencies that approach 50%, while others are found
much less frequently. There is some conceptual overlap
between rare SNPs (with minor allele frequencies of less
than 1%) and disease implicated mutations, but in com-
mon usage the term polymorphism is restricted to non-
pathogenic sequence changes. Genome SNP patterns are
fingerprints identifying subpopulations with common
heritage that potentially instigate subpopulation specific
traits exploitable for individualized treatment of disease.
For the purposes of this discussion, it is implicit that the
SNPs accumulate in the genome because they negligibly
affect survival, however, we recognize that some SNPs
may in fact have deleterious effects on the expression or
function of protein products.
Another distinction that is germane to the present
work is between synonymous and nonsynonymous
SNPs. SNPs that lie within the coding region are synon-
ymous if they do not change the amino acid specified by
the codon and are nonsynonymous when they do. Even
though synonymous SNPs will not change protein
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product by influencing the subcellular localization, stabi-
lity or translational efficiency of mRNA [1,2]. The non-
synonymous SNP introduces a single amino acid change
into the protein sequence. Assessing the impact of such
protein sequence changes on protein function can be
difficult. For most SNPs whose minor allele frequency is
at least 5%, it is likely that their impact on genetic fit-
ness is minor [3]. SNPs that clearly have harmful func-
tional consequences only rarely become more common
than this 5% level in the population as a whole. For less
common SNPs, homozygous individuals that have two
copies of the SNP are rare and deleterious consequences
can often be masked by the presence of the more com-
mon functional allele. Another factor in deciding the
significance of the nonsynonymous SNPs is genetic
redundancy. The affected gene could be one copy
among several present in the genome. These factors
decide the prevalence of the affected protein in the tis-
sues and may be more important for survival than how
the SNP affects protein function. Furthermore, a SNP
induced loss of functionality can sometimes be compen-
sated by redundant functionality in the larger physiolo-
gical system. An example is skeletal muscle where the
relative composition of the myosin isoforms depends on
environmental factors such as exercise [4-6] or zero
gravity [7]. The muscle tissue may adapt to loss of func-
tion in the SNP affected isoform to assure survival.
Finally, while SNPs accumulated in the data base are
identified world wide without apparent prejudice, they
are not necessarily a random sampling of the genome.
SNP frequency in different gene regions could reflect
uneven DNA sequencing accuracy and efficiency or
other unknown biases inadvertently built into the data
base. Our results are implications from the current data
base that changes and grows daily.
Here we identify and discuss the myosin heavy chain
nonsynonymous SNPs. We will include even scarce
SNPs where homozygous individuals are rare. We do so
in the spirit of being comprehensive, with the full
understanding that neutrality of function cannot be
assumed in these cases. Additionally, some SNPs dis-
cussed appear in the database, but have not been con-
firmed by other groups. Our purpose is to provide a
rationale for using these reports to investigate structure-
function relationships in myosin. Functional sub-
domains within myosin have emerged as disturbance
propagators essential to transduction. They are struc-
tural entities in which to identify SNP substitution sites
and focus speculation on how SNPs influence myosin
function.
The myosin heavy chain (MHC) consists of a globular
head domain called subfragment 1 (S1) and C-terminal
tail responsible for dimerization and cargo binding. In
muscle, myosin dimers form (thick) filaments with inter-
acting tails and head domains projecting outward from
the filament to associate with complementary actin
(thin) filaments in a muscle sarcomere [8]. Cellular
myosins have several forms [9-12]. The cellular myosin
V dimer is a processive motor utilizing the two heads
cooperatively to move along actin filaments [13].
S1 contains functional sub-domains that retain their
structure, but move relatively, during transduction [14].
ATPase transduction starts in the active site composed
in part by the P-loop, Switch 1, and Switch 2 polypep-
tides (linked to a 7-stranded b-sheet separating the
active site from the actin binding site) that sense the g-
phosphate position and coordination. ATP hydrolysis in
the active site is not followed immediately by phosphate
release because the Switch1R 2 4 6a n dS w i t c h2E 4 6 9
salt-bridge “back door” inhibits phosphate release until
actin binds. With actin binding, the back door opens to
release phosphate and the Switch 2 a-helix (or relay
helix) transmits linear force originating from the active
site to a converter domain converting linear force into
torque to rotate the lever-arm. The lever-arm a-helix,
rigidified by the bound myosin light chains (MLCs),
amplifies displacement and impels myosin relative to
actin [15,16]. A region between the switch 2 helix and
the converter domain, the SH2/SH1 hinge, undergoes
substantial conformation change during the transduc-
tion. The 7-stranded b-sheet, switch 2 helix, converter,
lever-arm, and SH2/SH1 hinge are the sub-domains
identified in the skeletal myosin crystal structure
depicted in Figure 1[17].
Multiple peptides within S1 (C-loop, Myopathy loop,
and others) constitute the actin binding site. This site
alternates between weak and strong actin binding affi-
nity in coordination with the lever-arm swing. Phos-
phate release in muscle myosin ATPase (or the opening
of the R246/E469 back door salt-bridge) is rate limiting
due to its inhibition by a large entropic energy barrier
in the absence of actin. Phosphate release initiates lever-
arm swing hence the rate limiting step inhibits progress
through the cycle until actin binds and a work produ-
cing lever-arm power stroke is possible. Coupling actin
binding to reducing the energy barrier to phosphate
release is an allosteric effect predicted for Myopathy or
C-loop structured surface loops [18,19]. We showed the
C-loop is the allosteric actin contact sensor mediating
bidirectionally between the actin-binding and active sites
[20]. The C-loop lowers the energy barrier to phosphate
release by coupling structural transitions within the S1
that allow phosphate release without inducing strain in
the 7-stranded b-sheet. Several actin binding myosin
surface loops are identified in Figure 1.
In this paper we locate nonsynonymous SNPs within
the functional sub-domains and evaluate their expected
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due is conserved among isoforms, ii) comparison of gen-
eral physical characteristics (size, charge, hydrophobicity,
etc.) between the native and substituted side chain, and
iii) (when possible) the hypothetical role of the native
residue in transduction and how this role could be
affected by the substituted side chain. We find that
SNPs infiltrate nearly every corner of the myosin head
and that their significance may lie in where they are tol-
erated in contrast to where they are excluded.
Results
Twenty-two human myosin heavy chain genes MYH1-4,
MYH6-15, MYH7B, MYOIE, MYO6, MYO7A and 7B,
MYO9A and 9B, and MYO10 were searched for nonsy-
nonymous SNPs as described in METHODS. We con-
fined the search to SNPs in the S1 domain. Table 1
summarizes results with the SNP reference number
locating it in the human genome and in the NCBI data
base, the sequence position relative to the skeletal myo-
sin 2× sequence, the MHC gene and myosin isoform it
encodes, the position for the SNP within myosin
domains, the average percentage of heterozygous genes
(one allele normal the other SNP substituted) in the
standard sub-populations, whether (Yes or No) there are
SNP substituted homozygous genes (both alleles SNP
substituted) in the standard sub-populations or observed
in screened individuals, and the number of individuals
screened. Missing data is denoted with a hyphen.
Most MHC isoforms contribute SNPs including the
fast skeletal muscle isoforms 2×, 2a, 2b, embryonic, and
perinatal; a- and b-cardiac myosins; smooth muscle var-
iants sm1A and sm2B; myosin V; super-fast myosin; two
isoforms of MYH14; MYH15; and other unconventional
myosins including IE, VI, VIIA, VIIB, IXA, IXB, and X.
Myosin 2b (MYH4) is a fast skeletal myosin isoform
apparently expressed in a skeletal jaw closing (masseter)
muscle [21]. The embryonic and perinatal isoforms
(MYH3 and 8) are developmentally regulated [22,23].
The embryonic isoform also expresses in regenerating
muscle and in extraocular muscles (EOM) [24]. A muta-
tion in perinatal myosin is implicated in a rare genetic
disease causing distal arthrogryposis syndrome [25]. The
a-cardiac isoform (MYH6) is predominantly expressed
in the atrium [26]. The b-cardiac isoform (MYH7) is
predominantly expressed in the heart ventriculum and
in slow or type 1 skeletal muscle fibers. Numerous heart
disease implicated mutations occur in the b-cardiac
MHC [27]. Another myosin isoform (MYH7B/MYH14)
on chromosome 20 is called a b-cardiac myosin with
85% homology with the b-cardiac myosin coded by
MYH7.
The MYH11 gene encodes the 4 smooth muscle myo-
sin isoforms that differ near the C-terminus (isoforms 1
and 2) or at Loop 1 where a seven amino acid peptide is
omitted (isoform A) or inserted (isoform B) [28]. The
Loop 1 insert correlates with tissue localization [29] and
enzyme kinetics [30,31]. Nucleotide-induced fluores-
cence intensity increase in the highly conserved W511
occurs in all but one myosin isoform implying it results
Figure 1 Several myosin peptides or domains identified with
energy transduction of ATP hydrolysis free energy to the
mechanical work of moving actin. Structured (Myopathy and
Cloop, AA363-377 and 404-417) and unstructured (Loops 2 and 3,
AA626-651 and 568-580) surface loops are actin binding peptides
(black). The 7-stranded b-sheet (green, AA116-127, 170-180, 248-257,
265-271, 458-468, and 671-678) mediates ATP hydrolysis and actin
binding affinity modulation. The Switch 2 helix (blue, AA469-509)
transmits translational movement in the active site to the converter
domain (red, AA716-772) where it is converted to the torque
needed to rotate the lever-arm (blue, AA773-813). The SH2/SH1
hinge (silver, AA688-715) undergoes a large conformation change
with lever-arm rotation. The function of SH3 (yellow, AA30-80) in
energy transduction is not yet understood. Not depicted are actin-
binding-peptides at two sites in the upper half of the molecule.
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a
SNP (rs number) Skeletal 2× sequence Skeletal 2× residue
if different
Gene Isoform Position
b <Hetero>
c
(Homo-zygotes?)
e
Count
d
7-stranded b-sheet (Figure 2)
61745307 I88M MYH13 super-fast near b1 --
442275 E89Q MYH6 a-cardiac near b1 0.5(N) 525
61739660 H98Q MYH1 2× near b1 --
2754166 D108E E108 MYH7 b-cardiac near b1 0(N) 525
7737765 H170Y R170 MYO10 myosin X b 4 --
61745058 D171E E171 MYH7B b-cardiac b 4 --
61745059 N172D MYH7B b-cardiac b 4 --
45516091 R240W MYH7 b-cardiac SW1 0(Y) 0
f
28934610 R246H MYO7A myosin VIIA SW1 - -
3218713 R252Q (disease implicated) MYH7 b-cardiac b 6 0(Y) 525
55645295 I253V MYH14 iso1/iso2 b 6 --
28936390 E257V T257 MYO6 myosin VI b6 --
34416201 T258K MYH13 super-fast b 6/b 7 2.5(N) 39
4299484 R445Q MYH15 unknown near b7 18.0(?) 1178
61731179 N447K MYH6 a-cardiac near b7 --
61745057 L463P MYH7B b-cardiac b 5 --
4981473 E469Q MYH7 b-cardiac SW2 0(N) 525
28932773 R675Q (disease implicated) MYH8 perinatal b 3 --
11539755 E681K MYOIE myosin 1e near b 3 --
Switch 2 helix (Figure 4)
61734198 Q478H MYH11 sm1A/sm2B SW2 hx - -
1064307 Y483H F483 MYO9B myosin IXB SW2 hx - -
28934903 N485I MYO7A myosin VIIA SW2 hx - -
61745301 H494D MYH13 super-fast SW2 hx - -
9868484 H495Y MYH15 unknown SW2 hx 38.3(Y) 1121
1052031 F497L MYO7A myosin VIIA SW2 hx - -
3218715 E502K (disease implicated) MYH7 b-cardiac SW2 hx 0(Y) 525
3729813 K505N MYH7 b-cardiac SW2 hx 0(N) 525
SH2/SH1 hinge, converter, & lever-arm (Figure 3)
73974725 M688V MYH1 2× SH2/SH1 hn - -
34515627 V694E L694 MYO7A myosin VIIA SH2/SH1 hn - -
41298143 R695H H695 MYO7A myosin VIIA SH2/SH1 hn - -
2190729 G701R MYH13 super-fast swivel 2.8(Y) 384
28940307 R707S MYH14 iso1/iso2 SH2/SH1 hn - -
3181426 R710S MYH7 b-cardiac SH2/SH1 hn - -
35641839 V720I (disease implicated) MYO7A myosin VIIA Converter - -
1136661 Y723C(disease imp)K723 MYO10 myosin X Converter - -
3746442 P735S (disease implicated) MYH7B b-cardiac Converter
g 525
26740 R743Q K743 MYO10 myosin X Converter 13.5(?) 1122
11847151 L785M MYH6 a-cardiac Lever-Arm 0(N) 525
36090425 D787N Q787 MYO7A myosin VIIA Lever-Arm - -
3218716 A801T (disease implicated) MYH7 b-cardiac LA & ELC IQ 0(Y) 690
SH3 (Figure 5)
17092199 P31T MYH7B b-cardiac SH3 discordant(?)
h 1013
28711516 G57R MYH6 a-cardiac SH3 -(Y) -
17707947 V60I MYO10 myosin X SH3 12.9(?) 1092
41309316 K68N A68 MYH7B b-cardiac SH3 - -
Actin binding (Figure 6)
45629132 R370H K370 MYO7A myosin VIIA C-loop - -
35222064 Q371P MYH13 super-fast C-loop 2.5(N) 39
Burghardt et al. BMC Genomics 2010, 11:172
http://www.biomedcentral.com/1471-2164/11/172
Page 4 of 20Table 1: Myosin heavy chain SNPs
a (Continued)
2515926 P378Q MYH6 a-cardiac C-loop - -
3218714 R406W (disease implicated) MYH7 b-cardiac Myopathy 0(Y) 525
45522831 R408C K408 MYH7B b-cardiac Myopathy - -
35349985 F534L MYH4 2b actin bind 2.8(N) 39
59922029 R570K K570 MYO10 myosin X Loop 3 - -
61735348 V572A/D A572 MYH3 embryonic Loop 3 - -
28565077 A621V MYH15 unknown near Loop 2 - -
61745053 T631N E631 MYH7B b-cardiac Loop 2 - -
34693726 A637V G637 MYH8 perinatal Loop 2 9.2(N) 310
2276282 E643K K643 MYO7A myosin VIIA Loop 2 - -
61743282 F655S MYO7B myosin VIIB actin bind - -
N-term, U50, and L50
3729993 D4A MYH7 b-cardiac N-term 0(Y) 525
34042358 D4E MYH13 super-fast N-term 3.2(?) 62
45511396 R18C MYH7 b-cardiac N-term 0.4(Y) 0
f
61730792 R24P/L MYH1 2× N-term - -
41312286 T25M I25 MYH7B b-cardiac N-term - -
590722 P(<32)T
i - MYH14 iso1/iso2 undefined - -
2404991 G(<48)S
i - MYO7B myosin VIIB undefined - -
1052030 L(<58)S
i - MYO7A myosin VIIA undefined - -
35218876 R(<64)Q - MYO9B myosin IXB undefined 2.5(?) 39
10518970 P(<82)L
i - MYO9A myosin IXA undefined 4.3(?) 1224
17855105 R(<82)K
i - MYO9A myosin IXA undefined - -
2929516 T(<82)I
i - MYO9A myosin IXA undefined discordant(?)
h 1122
34773557 M142I A142 MYH14 iso1/iso2 N-term 2.8(?) 70
6174305 R145G G145 MYO10 myosin X N-term - -
41298131 I148T R148 MYO7A myosin VIIA N-term - -
58359270 L199F I199 MYO9B myosin IXB N-term - -
28936391 H287R MYO6 myosin VI U50 - -
6870170 E300D L300 MYO10 myosin X U50 1.3(?) 908
35512085 T307P MYH4 2b U50 - -
34498817 P320A E320 MYH14 iso1/iso2 U50 5.5(?) 309
35315400 S323C V323 MYH14 iso1/iso2 U50 2.5(?) 78
34124921 I326T MYH8 perinatal U50 1.2(N) 39
35984286 Q329R (disease implicated) MYH4 2b U50 2.5(N) 39
34846075 V335I T335 MYO10 myosin X U50 2.5(?) 39
41298135 R336H D336 MYO7A myosin VIIA U50 - -
34419805 T345A MYH8 perinatal U50 2.8(N) 35
61756677 V350D/A MYH2 2a U50 - -
11750538 R350W V350 MYO10 myosin X U50 50(?) 1264
1724577 E389D Y389 MYH12 myosin V U50 17.2(Y) 1262
61732664 Y(389-390)H
j MYO6 myosin VI U50 - -
61742021 I514T (disease implicated) MYO7B myosin VIIB L50 - -
12949680 A594T MYH4 2b L50 7.4(N) 39
a Abbreviations SW1 or SW2 denote Switch 1 or 2, hx is helix, sb is salt-bridge, hn is hinge, and hyphen (-) is
no data submitted.
b Position names are defined in the MHC sequence as follows:
1. SH3 like b-barrel: AA30-80
2. 7-stranded b-sheet: b1 AA116-120; b2 121-127; b3 671-678; b4 170-180; b5 458-468; b6 248-257; b7 265-271
3. Loop 1 AA200-220
4. Upper 50 k (U50) AA220-468
5. C-loop AA363-377
6. Myopathy loop AA404-417
7. Switch 2 helix AA469-509
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The smA isoform has nucleotide-induced tryptophan
fluorescence enhancement like other myosin isoforms
but we showed with site-directed mutagenesis that the
contributing tryptophan is probably not W511. These
results suggested that smA and smB myosin isoforms
have different influence propagating pathways emanating
from the active site through the switch 2 helix contain-
ing W511 to the converter domain [32].
Processive myosin V (MYH12) translates over actin
filaments using a hand-over-hand mechanism [33-35].
The super-fast isoform (MYH13) expresses in EOMs
performing diverse functions including eye movement
[24]. The EOMs are more complex than limb muscles
with 9 or more different MHCs expressed in adult mus-
cle including the fast skeletal, b-cardiac, and embryonic
MHC. The super-fast myosin supports higher velocity
and lower tension contractions [36]. The MYH14 gene
codes for 2 myosin isoforms (iso1/iso2 in Table 1)
expressed in muscle and non muscle tissue. The
MYH14 gene is implicated in hearing disorders [37].
SNP variants in MYH15 are associated with elevated
risk for heart disease [38].
Myosin IE (MYOIE) is a cellular myosin with an
extended C-loop thought to interact with tropomyosin
in tropomyosin-containing actin [39,40]. Myosin VI is a
reversedirection motor with core structure resembling
forward-direction motors except for two inserts (1 & 2).
Insert 1, near the active site and Switch 1, is probably
partially responsible for the slow ADP release
(A·M^·D®A·M in Scheme 1, METHODS)[41]. Insert 2
modifies the converter domain to re-direct lever-arm
swing for reverse-directed motility [41,42]. Mutations in
myosin VII Aassociate with Us her syndrome that in its
most severe phenotype is a deafness-blindness disorder
[43,44]. Myosin IXB is a single headed processive motor
that is unique because its rate limiting step is not ADP
release but ATP hydrolysis (M*·T®M**·D·P in Scheme
1) suggesting it remains actin bound even in a weak
actin binding state [45]. Slow dissociation from actin is
attributed to tethering by a unique Loop 2 insertion.
Myosin X is a membrane associated motor involved in
filopodia motility [46] that has novel monomeric and
dimeric conformations at physiological protein concen-
trations [11]. Calmodulin or calmodulin like protein
(CLP) are the lever-arm bound myosin light chains in
myosin X [47]. Myosin X is believed to be processive
consistent with its function in the cell.
SNP implications for motor function
Three SNPs, R246H, E469Q (Figure 2) and G701R (Fig-
ure 3), are remarkable because of the functional signifi-
cance of the residues they modify. R246 and E469 form
the Switch 1/Switch 2 salt-bridge at the g-phosphate in
bound ATP preventing product release following hydro-
lysis in the active site of S1. Site-directed mutagenesis of
Dictyostelium discoideum (Dicty) myosin produced
R246E, E469R, and the double mutant R246E/E469R
reversing the polarity of the salt-bridge [48]. Only the
double mutant remained functional but with altered
ATPase kinetics. Similar experiments using expressed
smooth muscle myosin suggested R246 is significant for
back door closure after ATP binding to the active site
and that E469 is important for ATP hydrolysis by its
positioning of a water molecule for nucleophilic attack
on the g-phosphate [49]. The E469Q SNP substitution
does not necessarily prohibit the latter mechanism
although E469A/R mutants eliminated the phosphate
burst and actin-activated ATPase. The R246H SNP sub-
stitution alters size but not charge of the side chain
while R246A/E mutants likewise eliminated the phos-
phate burst and actin-activated ATPase. The loss of the
8. Lower 50 k (L50) AA469-620
9. Actin binding peptides: hydrophobic helical peptides AA529-560 and 652-661, Loop 2, Loop 3,
C–loop, Myopathy loop
10. Loop 3 actin binding site: AA568-580
11. Strut loop: AA600-604
12. Loop 2 AA626-651
13. SH2/SH1 hinge AA688-715
14. Converter domain: AA716-772
15. Lever-arm AA773-813
cAverage percentage of heterozygous genes (one allele normal, the other SNP substituted) in the standard subpopulations.
d Individuals sequenced.
e Are there SNP substituted homozygous genes (both alleles SNP substituted) in the standard sub-populations or
observed in screened individuals?
f Unexplained inconsistency.
g All individuals sequenced are homozygous in the SNP replacement over 4 population groups.
h Discordant genotype implies conflicting reports.
i Sequence segment not aligned in BLAST.
j Sequence segment SLEYCAE in myosin VI inserts between AA389 and 390 in MYH1. This is not Insert 1 or
2 mentioned in the text.
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t h ep h o s p h a t er e l e a s es t e pi sn ol o n g e rr a t el i m i t i n g
undermining the efficient energy transduction in muscle
because the ATPase cycle disengages from the work
producing interaction with actin. The SNPs suggests it
would be interesting to test the R246H and E469Q sub-
stitutions in an in vitro system. R246H occurs in myosin
VIIA where ATPase is rate limited by ADP release
rather than phosphate release possibly explaining its tol-
erance to substitution. E469Q occurs in b-cardiac myo-
sin where ATPase is rate limited by phosphate release.
R246H and E469Q occur with unknown or apparently
low probability for expression, respectively.
G701R in super-fast myosin replaces the glycine swivel
with a residue containing a bulky side chain inhibiting
free rotation in the Ramachandran angles that is charac-
teristic only to glycine [50]. The highly conserved G701
pivot was found to be essential for motor activity in ske-
letal [51] and Dicty [52] myosins. S1 crystal structures
depicting myosin conformation in M** [53] and M* [17]
lever-arm orientation states indicate G701 swivels 40-50
deg about two axes with thel e v e r - a r ms w i n g[ 5 4 ] .
Unlike nearby swivel-candidate residues, G705 and
G712, the G701 maintains conformations in the pre-
and post-powerstroke states that only glycine can readily
accommodate. If the G701R substituted protein truly
functions in healthy individuals, it suggests the super-
fast myosin has a substantially modified transduction
mechanism to accomplish its high velocity contraction.
The G701R substitution occurs with an average hetero-
zygous population in percent (AHP) of 2.8% and with
homozygous individuals identified.
Figure 2 shows the 7-stranded b-sheet separating the
active from the actin binding sites and numerous
Figure 2 The 7-stranded b-sheet (green) and the adjacent structures (red). SNP substitution sites in the vicinity are depicted in grey or
yellow with space filling models of the unsubstituted side chains. The yellow residues are also implicated in disease. SNP residue annotation
color coding corresponds to: cardiac myosin II (red), skeletal myosin II (blue), non-muscle myosin II (brown), and unconventional myosin (tan).
Residues annotated in black are not SNPs. The 7 strands are numbered at the tip indicating the sequence number increasing direction. R675 on
b3 (AA671-678); R170, E171, and N172 on b4 (AA170-180); L463 on b5 (AA458-468); and R252, I253, and T257 on b6 (AA248-257) modify the
structure. E681 is three residues past the end of b3, E469 is on Switch 2 just two residues past the end of b5, R240 and R246 are on Switch 1 just
before the start of b6, and T258 lies between b6 and b7 (AA265-271). Residues I88, E89, H98, E108, R445, and N447 are distant in sequence but
spatially associated with the 7-stranded b-sheet structure. E89 is the most distant at ~7.5 angstroms. Blue side chains for residues Y458 and I460
are not SNPs but are proposed to contribute substantially to the energy barrier determining the rate limiting step to myosin ATPase product
release in the absence of actin.
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H170Y (R170 in MYH1), D171E (E171 in MYH1), and
N172D modify b4; L463P modifies b5; while I253V and
E257V (T257 in MYH1) modify b6 within the b-sheet
structure. SNP substitution R675Q modifying b3 is
implicated distal arthrogryposis syndrome [25] and in
heart disease together with SNP substitution R252Q
modifying b6 [27]. The R/Q substitution replaces a large
+charged side chain with a polar, neutral, and smaller
side chain where total surface area changes by ~52 Å
2.
I/V, D/E, H/Y and N/D substitutions are conservative of
charge, size, and polarity. E/V substitution is not
conservative of charge, size, or polarity. The L/P substi-
tution could be the most perturbative due to proline’s
backbone restrictive geometry inducing strain in the b-
sheet. Distortions in this b-sheet accompany events
associated with ATP hydrolysis and product release
since the P-loop, Switch 1, and Switch 2 are closely
linked with the b4, b6,a n db5 strands, respectively [55].
Furthermore, crystal structures of myosin V without
bound nucleotide models the actin-attached rigor con-
formation and suggests strong binding with actin closes
a cleft within the 50 kDa domain of S1 [56] causing dis-
tortions in the b1, b2,a n db3 s t r a n d s[ 5 5 ] .T h u sm a n y
Figure 3 The SH2/SH1 hinge (silver, AA688-715), converter (red, AA716-772), and lever-arm (blue, AA773-813). SNP residue annotation
color coding corresponds to: cardiac myosin II (red), skeletal myosin II (blue), non-muscle myosin II (brown), and unconventional myosin (tan).
Thirteen SNP substitution sites at M688, L694, H695, G701, R707, R710, V720, K723, P735, K743, L785, Q787, and A801 are depicted in gray or
yellow with space filling models of the unsubstituted side chains. The yellow residues are also implicated in disease. R710 is adjacent to the
reactive thiol residue (SH1 at C709) on the SH2/SH1 hinge. L785, Q787, and A801 are on the lever-arm and within the ELC binding region. The
converter domain receives impulses from the Switch 2 helix that it converts into the torque needed rotate the lever-arm while the SH2/SH1
hinge changes conformation.
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sheet and in particular, strands 3-6 containing the SNP
substitutions. Our MCMD simulation suggests distor-
tion of the b-sheet in the b5 and b7 strands provides a
substantial part of the entropy dominated energy barrier
to product release in the absence of actin [19]. In parti-
cular, b5 residues Y458 and I460 (Figure 2) have solvent
accessible surface areas (ASA) that undergo dramatic
increases with barrier transition contributing signifi-
cantly to the entropy dominated free energy barrier.
Simulation suggests residues on b5 and b7 should more
likely perturb the contraction mechanism implying the
SNP substitution L463P modifying b5 may again have
special significance. These SNPs occur in a variety of
myosin genes and isoforms but most (including L463P)
are relatively new entries that have not undergone
further verification to test their presence in sub-popula-
tion data bases.
Figure 2 also shows Switch 1 and the R240W and
R246H SNP sites adjacent to the 7-stranded b-sheet,
E681K adjacent to b3, Switch 2 and the E469Q SNP site
adjacent to b5, T258K appearing between the b6
(AA248-257) and b7 (AA265-271) strands, and D108E
(E108 in MYH1) upstream from b1 and adjacent to the
7-stranded b-sheet. Additionally, I88M, E89Q, and
H98Q are within a few angstroms of b1, while R445Q
and N447K are within a few angstroms of b7.T h e
R240W substitution provides an opportunity to insert a
harmless spectroscopic probe (i.e., W240) into the
Switch 1 peptide to sense directly the back-door
dynamics and induced strain in the 7-stranded b-sheet.
The D108E SNP reiterates the natural cardiac/skeletal
myosin isoform sequence substitution. I88M, E89Q, and
H98Q connect the 7-stranded b-sheet to SH3. N447K
appears within a cluster of heart disease linked muta-
tions [27]. R445Q has an AHP of 18% and comes from
MYH15. The next largest AHP SNP at 2.5% from
around the 7-stranded b-sheet is T258K in super-fast
myosin. Seventeen SNP substitutions (excluding disease
linked R252Q and R675Q) in, or proximal to, the 58
residue 7-stranded b-sheet is unexpected given the sig-
nificance attributed to the region.
Figure 4 shows the Switch 2 helix underlying the 7-
stranded b-sheet where b5 and the Switch 2 helix are
linked by Switch 2, and sites for the eight SNP substitu-
tions, Q478H, Y483H (F483 in MYH1), N485I, H494D,
H495Y, F497L, and K505N, modifying the Switch 2
helix. SNP substitution E502K is implicated in heart dis-
ease [27]. The Switch 2 a-helix transmits linear force
originating from the active site to the converter domain.
Helix rigidity could be essential to force transmission.
Q478 is a highly conserved residue at the beginning of
Figure 4 The 7-stranded b-sheet (green), Switch 2, and the Switch 2 helix (blue). SNP residue annotation color coding corresponds to:
cardiac myosin II (red), skeletal myosin II (blue), smooth muscle myosin II (green), non-muscle myosin II (brown), and unconventional myosin
(tan). Eight SNP substitution sites at Q478, F483, N485, H494, H495, F497, E502, and K505 on the Switch 2 helix are depicted in gray or yellow
with space filling models of the unsubstituted side chains. The yellow residue is also implicated in disease. Movement at Switch 2 propagates to
the Switch 2 helix and to the converter domain (not shown) via the tip of the helix near K505.
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sion efficiency by reducing rigidity. The Q478H substi-
t u t i o nt e s t st h i sh y p o t h e s i sb e c a u s et h eQ / H
substitution is helix destabilizing [57] suggesting helix
stability may not be crucial. Other SNP substitutions,
N485I, H495Y, F497L and E502K, are helix stabilizing
while Y483H, H494D and K505N are destabilizing.
K505N is at the C-terminal end of the helix where
destabilization would be least detrimental. H495 is a
potentially sensitive point where the helix develops a
kink in the pre-power stroke M** conformation [53].
The H495Y substitution from MYH15 has an AHP of
38% and homozygous individuals were identified. A
H495W mutation might sense Switch 2 helix movement
by tryptophan fluorescence changes and represents a
desirable signal donor in the transduction mechanism.
Highly conserved residues on the tip of the switch 2
helix, Y504 and I509, are thought to mediate interaction
with the converter domain but are not affected by
known SNPs.
Figure 3 shows the SNP substitutions sites for the
SH2/SH1 hinge [M688V, V694E (L694 in MYH1),
R695H (H695 in MYH1), G701R, R707S, R710S], con-
verter [R743Q (K743 in MYH1)], and lever-arm [L785M
and D787N (Q787 in MYH1)]. SNP substitutions V720I,
Y723C, and P735S in the converter, and A801T in the
lever-arm, are implicated in heart disease [27]. The con-
verter domain position P735 is implicated is heart dis-
ease by a P735L substitution in b-cardiac MHC [27].
The P735S SNP replacement is homozygous in the 4
subpopulation groups tested suggesting the reference
sequence is incorrect.
The converter domain has been implicated as the ele-
ment undergoing elastic distortion in the myosin
accompanying force development prior to mechanical
work production [58,59]. Site directed mutagenesis in
the SH2/SH1 hinge–converter interface, and in the con-
verter domain proper, provided clues for how it per-
forms the conversion of linear translation in the Switch
2 helix to the rotation of the lever-arm [60]. Mutations
F713A or F768A completely eliminated or sharply inhib-
ited the ability of smooth muscle myosin to function
mechanically. Standard kinetics experiments looking at
the ATP binding, hydrolysis, product release, and the
fluorescence from the ATP sensitive tryptophan (W511)
indicate active site kinetics and transmission of force
through the Switch 2 helix are fully intact in the
mutants. The findings suggest that the mutations per-
turb only the converter function. Other experiments,
specifically fluorescence resonance energy transfer
(FRET), actin sliding assay, and single myosin force
development show that both mutants are compromised
mechanically. The F713A mutant causes a catastrophic
mechanical failure due to the loss of the hydrophobic
contact between the SH2/SH1 hinge and converter. The
F768A mutant looses the rigidity of the Switch 2 helix/
converter contact at F768 making a motor that can
rotate its lever-arm but with less force. The SH2/SH1
hinge has a high density of SNP substitutions with 6
occurring in a 28 residue peptide. SNP sites at R707 and
R710 are highly conserved among myosin isoforms but
do not appear to enter into the crucial interaction with
the converter domain. M688 is not conserved among
the myosin isoforms.
T h es o l ec o n v e r t e rd o m a i nS N Ps u b s t i t u t i o nn o t
implicated in disease is R743Q that is also common
with an AHP of 13.5%. The SNP occurs in myosin X
that has a low converter domain sequence homology
with myosin 2×. Myosin VI, VII, and X have a unique
structure at the head-tail junction wherein a monomeric
single a-helix (SAH) competes with the dimeric coiled-
coil [9-11]. The SAH domain might function as an elas-
tic element undermining converter domain significance
in this isoform. Hypothetically, the converter domain is
sensitive to mutation because it usually needs to per-
form the two functions of the linear-to-rotary motion
converter and elastic element.
The L785M, D787N (Q787 in MYH1), and A801T
SNP substitutions modify the leverarm. Mutation in this
region could interfere with essential light chain (ELC)
binding. The loss of light chains, either regulatory (RLC)
or ELC, affects myosin morphology and its motor func-
tion probably by lowering the rigidity of the lever-arm
domain [61]. Either substitution could also directly per-
turb the lever-arm structure and rigidity also leading to
loss of function. None of these possibilities may be hap-
pening due to the lever-arm SNP substitutions because
their consequences would be severe. Aside from G701R
and R743Q, SNPs shown in Figure 3 affect a small or
unknown percentage of the population.
Figure 5 shows the SH3 domain (AA30-80) and the
sites for the P31T, G57R, V60I, and K68N (A68 in
MYH1) substitutions. The SH3 domain is a b-barrel
located close to the myosin active site but with uncer-
tain function. The SH3 domain undergoes significant
conformational change during ATP hydrolysis including
at the G57 site where Ramachandran angle changes con-
sistent with a glycine residue will be inhibited by steric
clash with the arginine side chain. Smooth muscle myo-
sin contains tryptophan residues in SH3 and its vicinity
that sense conformational change in the N-terminal
domain with nucleotide binding to the active site [62].
N-terminus truncated constructs of the Dicty S1 showed
SH3 played a role is structural stabilization of S1 and in
communication among functional domain within the
myosin head [63].
The essential light chain (ELC) appears to couple SH3
and lever-arm sub-domains in S1. LC1 and LC3 are
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heavy chain binding LC1/RLC or LC3/RLC pairs in
equal amounts. LC1 differs from LC3 by a 40 residue
extension at the N-terminus. Cardiac myosin has only
LC1. The flexible LC1 N-terminus is not resolved in S1
crystal structures and is not shown in Figure 1. Electron
cryomicroscopy reconstructions suggest SH3 and the N-
terminus of LC1 interact in skeletal muscle myosin [64].
There it is suggested that the SH3/LC1 interaction
could facilitate the (N-term)LC1/(N-term)actin interac-
tion known to affect the overall actomyosin interaction
in skeletal and cardiac myosins [65,66] and that SH3
could contain an LC1/active-site path of influence
known to modulate myosin ATPase [67]. The P31T sub-
stitution in MYH14 and V60I in myosin X are common.
SNP implications for actomyosin
Protein-protein contacts in actomyosin were identified
by experimental structural studies combined with simu-
lated docking of the myosin and actin crystal structures
[68-72], by detecting changes in actin binding strength,
actin-activated myosin ATPase, and in vitro motility
caused by the mutation of small peptide segments or
individual residues in myosin [73-81]. Primary hydro-
phobic actin contacts are helical segments, AA529-560
and AA652-661, while the unstructured surface Loop 2
(AA626-651) maintains ionic interactions with the actin
N-terminus. Secondary sites are an unstructured surface
loop, Loop 3 (AA568-580), and the structured Myopathy
loop (AA404-417) [68] also on the S1 surface. Figure 6
shows the actin binding myosin surface loops including
Figure 5 The SH3 domain (yellow, AA30-80) and 4 SNP substitution sites at P31, G57, V60, and A68 are depicted in gray with space
filling models of the unsubstituted side chains. SNP residue annotation color coding corresponds to: cardiac myosin II (red), non-muscle
myosin II (brown), and unconventional myosin (tan). The function of SH3 is unknown but it is implicated in transmission of influence from ELC
to the active site and in supporting the binding of the ELC N-terminus to actin. Several SNP substituted residues adjacent to the 7-stranded b-
sheet (Figure 2) are also adjacent to SH3 including I88, E89, H98, and E108.
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binding site SNP substitutions F534L and F655S that fall
within a primary hydrophobic actin contact.
Experimental work comparing tertiary structure of
skeletal and b-cardiac MHC identified the C-loop
(AA363-377), Figures 1 and 6, having influence on
active site coupling to actin and possibly a direct inter-
action with actin [82]. Limited proteolysis of skeletal S1
cleaves the heavy chain at Loop 1 (AA200-220) and
Loop 2 producing 25, 50, and 20 kDa molecular mass
fragments [83]. These loops are involved in regulation
of substrate release (Loop 1) and in actin binding and
regulation of actin-activated ATPase (Loop 2)
[75,78,84-86]. Limited proteolysis of bS1 cleaves the
heavy chain at equivalent points and at the C-loop
within the 50 kDa fragment [82]. The C-loop cleavage
dramatically affects bS1 Mg
++ATPase suggesting it parti-
cipates in energy transduction [82]. Actin binding pro-
tected Loop 2 from proteolysis in skeletal S1 indicating
Loop 2 involvement in actin binding [87,88]. Actin bind-
ing to bS1 fails to inhibit Loop 2 cleavage [82,89] but
does inhibit C-loop cleavage [82]. These observations
highlight differences in skeletal S1 and bS1 conforma-
tion and identify the C-loop as a possible actin binding
site. The C-loop was proposed as a site of actin binding
in skeletal S1 [71,72], in myosin V [90], and in myosin
IE where it is called Loop 4 [39]. We constructed single
site mutations in the smooth muscle myosin C-loop and
chimeric proteins containing C-loop sequences from
bS1 and skeletal S1 to investigate how sequence per-
turbs C-loop function [20,91]. Based on this work we
proposed that the C-loop is an allosteric actin contact
sensor initiating actin-activation of the myosin ATPase.
The C-loop SNP substitutions, R370H (K370 in
MYH1), Q371P, and P378Q, occur in the myosin VIIA,
super-fast myosin and a-cardiac myosin, respectively. In
super-fast myosin, the Q/P substitution can be expected
to perturb and rigidify the C-loop structure with the
proline. We proposed structural rigidity in the C-loop is
probably necessary for its effectiveness [19] but overall
structure also plays a role and impacts myosin kinetics
[20]. Each of these substitutions is expected to affect
myosin kinetics related to its interaction with actin, e.g.
actin-activated ATPase and motility. Heterozygous
Figure 6 Elements of the actin binding site on S1. Structured surface loops (Myopathy and Cloop, AA404-417 and 363-377), unstructured
surface loops (Loops 2 and 3, AA626-651 and 568-580), and F534 and F655 in the primary hydrophobic actin contacts (AA529-560 and 652-661)
are actin binding peptides. SNP residue annotation color coding corresponds to: cardiac myosin II (red), skeletal myosin II (blue), non-muscle
myosin II (brown), and unconventional myosin (tan). Thirteen SNP substitution sites K370, Q371 and P378 (C-loop); R406 and K408 (Myopathy
loop); F534 and F655 (primary hydrophobic contact); K570 and A572 (Loop 3), and, A621, E631, G637, and K643 (Loop 2) are depicted in gray or
yellow with space filling models of the unsubstituted side chains. The yellow residue is also implicated in disease.
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homozygous individuals were detected. Abundance of
the other SNPs is untested.
Loop 2 and near Loop 2 SNP substitutions are A621V,
T631N (E631 in MYH1), A637V (G637 in MYH1), and
E643K (K643 in MYH1). A/V substitution replaces the
apolar alanine with the larger apolar valine, T/N
exchanges two neutral polar groups, and E/K reverses
charge. The effect of Loop 2 on myosin ATPase and
myosin interaction with actin has been thoroughly stu-
died with site directed mutagenesis. In Dicty myosin II,
Loop 2 tolerates significant sequence changes without
affecting function. Function seems to depend on
charged or apolar residue distribution but not on speci-
fic structural features because the loop is flexible. A/V
and T/N substitutions are conservative and unlikely to
impact function. The A637V substitution is from perina-
tal myosin and abundant in this isoform although no
homozygous individuals were detected. Abundance of
the other Loop 2 SNPs is untested.
The Myopathy Loop is a structured surface loop con-
taining an unusual clustering of heart disease implicated
mutations including R406Q/W/L, V407M, V409M, and
G410V [27]. It was shown to be an actin binding site
[69,92] and modulator of actin activated ATPase [81,93].
At R406, the smooth muscle heavy meromyosin (HMM)
model for b-cardiac myosin has largely reiterated the
clinical phenotype [94]. The G410V mutant shows mod-
est changes in actomyosin affinity possibly indicating a
generally degraded fit between myosin and actin like the
R406 mutants [20]. The R406W mutant appears in the
S N Pd a t ab a s ei na p p a r e n t l yh e a l t h yi n d i v i d u a l s .R 4 0 8 C
(K408 in MYH1) has not been implicated in disease.
None of the Myopathy loop SNPs have significant abun-
dance although homozygous individuals carrying
R406W were identified.
The Loop 3 SNP substitutions, R570K (K570 in
MYH1) and V572A/D (A572 in MYH1), and the hydro-
phobic actin binding site residue substitutions, F534L
and F655S, are conservative except for F655S. Among
the myosin isoforms, all of these residues are variable.
The heterozygous allele for F534L in skeletal myosin 2b
has significant abundance (2.8%) but no homozygous
individuals were identified.
Other myosin S1 SNPs
SNPs appearing in Table 1 but not discussed in the con-
text of Figures 2, 3, 4, 5, and 6 locate to the N-terminus
(AA1-219), the upper 50 k (AA220-468) and lower 50 k
(AA469-620). The upper 50 k and lower 50 k domains
(U50 and L50) designate peptides within the 50 k of S1
on either side of the cleft that closes on strong binding
to actin. N-term SNP substitutions include D4A in
MYH7 and D4E in MYH13, R18C, R24P/L, T25M (I25
in MYH1), M142I (A142 in MYH1), R145G (G145 in
MYH1), I148T (R148 in MYH1), and L199F (I199 in
MYH1). The U50 SNP substitutions include H287R,
E300D (L300 in MYH1), T307P, P320A (E320 in
MYH1), S323C (V323 in MYH1), I326T, V335I (T335 in
MYH1), R336H (D335 in MYH1), T345A, V350D/A
from myosin 2b and R350W (V350 in MYH1) from
myosin X. L50 SNP substitutions are I514T and A594T.
SNP substitutions Q329R and I514T are disease impli-
cated. SNPs in the “other myosin S1” category do not
fall within, or are not spatially proximal to, presently
recognized S1 functional elements directly participating
in transduction. The average heterozygous SNP allele
frequency for this set ranges from 0 to 17.2% (17.2% for
E389D in myosin V with homozygous individuals identi-
fied) with most heterozygous substitutions having signif-
icant abundance and some untested.
Identifying sites for probing motor dynamics
Figure 7 shows the amino acid sequence of myosin 2×
vs AHP for the SNPs in Table 1. Myosin regions or
domains identified with specific functions in energy
transduction are identified by the broken red line and
with a vertical label. Many SNPs have unknown or zero
AHP that are both plotted as zero. The remaining sub-
stitution sites have a significant-to-large AHP and are
identified with a horizontal label. Healthy individuals
with homozygous SNP substituted alleles are implied by
the significant heterozygous populations. Figure 7A, spe-
cifying SNPs in the AA1-400 portion of the MHC show
numerous substitutions at the N-terminus and in the
AA280-360 peptide segments. These regions are not
directly related to core function because they do not fall
into the identified functional subdomains. The C-loop
and b6-b7 junction are functional elements that are the
exceptions in this region because they are SNP modified.
Figure 7B, specifying SNPs in the AA401-813 portion of
the MHC, shows a somewhat different picture with all
but one significant SNP substitution modifying a func-
tional sub-domain. The high AHP sites are candidates
for modification by mutagenesis to introduce probes
that monitor motor dynamical structure without altering
native behavior. Most crucial regions are covered where
in introduction of Trp or Cys would facilitate direct
(Trp) or indirect, through a specific modification by an
extrinsic probe (Cys), observation of myosin dynamics.
Remarkably, the G701R substitution in the SH2/SH1
hinge falls into this category.
Discussion
SNPs account for about 75% of the number of sequence
differences between individuals in a population [95].
They have significant utility in gene mapping studies
and there are an increasing number of SNPs that have
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dual’s susceptibility to disease and response to various
drug therapies. In some well-studied genes and gene
families, patterns of SNPs within the coding sequences
have also provided some insight into protein function.
Perhaps the best known example of this is the SNP
(rs334) that leads to sickle cell anemia. This Glu6Val
change in the protein sequence has an allele frequency
of about 25% in Yoruban populations and creates well-
known negative and presumed positive consequences for
the individuals that carry this sequence variant. Myosin
SNPs could likewise create negative and positive conse-
quences for certain populations with specific functional
requirements that should be explored experimentally.
Nonsynonymous SNPs that have truly neutral functional
consequences also provide important information about
Figure 7 Function-neutral candidate SNP missense substitutions in myosin heavy chain. The x-axis is the myosin 2× (MYH1) sequence
from 1-400 in Panel A and 401-812 in Panel B. The y-axis indicates AHP in percent. Substitutions with AHP ≥ 0.5% are denoted by a vertical
bar and by the residue substitution and sequence number in a horizontal label. The thick broken horizontal red line indicates myosin functional
domain positions described in the text. Domain names are denoted with vertical labels. Converter domain (Panel B) SNP substitution P735S has
an AHP showing 100% substitution in the 4 subpopulations tested suggesting the reference sequence is incorrect.
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tein structure that are tolerant of structural variation.
We discuss three scenarios for interpreting SNP data
denoted, the function-neutral, the too-robust, and the
too-sensitive.
SNPs reside in healthy people, otherwise they are
deleted by natural selection, hence it might be hypothe-
sized that the amino acid substitution is function-neu-
tral. In this case, SNPs identify residues or components
of the motor not directly related to core function mak-
ing them candidate sites for adventitious modification.
An example is the R240W substitution that places a
spectroscopic probe in the 7-stranded b-sheet at the
interface of the active and actin-binding sites. It is
thought that coordination of ATP hydrolysis with actin
binding and release is mediated by this b-sheet and an
optical probe of its structure would be valuable. R240 is
not highly conserved among species but infrequently
substituted by aromatic residues. Its negligible AHP
raises uncertainty about potential use although homozy-
gous individuals were reported. G701 is the pivot for the
lever-arm swing and thought to be necessary for myosin
function. The G701R SNP substitution has 2.8% AHP
but it is difficult to understand how this substitution
could be function-neutral in the swinging lever-arm pic-
ture for force production. Other unlikely function-neu-
tral candidates are the R246H and E469Q substitutions
with unknown and insignificant AHP, respectively. R246
and E469 form the SW1/SW2 salt-bridge regulating
phosphate release in ATPase in the rate limiting step for
muscle myosins. R246H originates from the cellular
myosin VII isoform where the native rate limiting ADP
release minimizes R246 significance. E469Q originates
from b-cardiac myosin using the phosphate release
mechanism. Under the function-neutral hypothesis, the
collection of SNPs at R246, E469 and the vicinity of the
7-stranded b-sheet would imply a diminished role for
this structure in energy transduction.
Figure 7 identifies the most likely candidates for the
function-neutral SNPs because they have significant to
large AHP implying the presence of healthy individuals
carrying homozygous substituted alleles. Here SNPs clus-
ter in a few regions of the myosin head not identified with
core functionality but also cover most function-crucial
regions in the S1. SNPs in Figure 7 may be most useful as
leads for the introduction of probes that monitor motor
dynamical structure without altering native behavior.
An alternative to the function-neutral hypothesis is
that SNP substitutions modify functional structures too-
robust to be disturbed by otherwise intrusive sequence
changes. Excluding for a moment the E469Q and
G701R special cases, several structures in S1 fulfill
expectations implied by this hypothesis. The 7-stranded
b-sheet and vicinity collected 17 SNP substitution sites
(excluding known disease related sites, see Table 1) over
14 of the 22 myosin genes where SNPs were identified.
The too-robust hypothesis implies that the energy trans-
duction mechanism contained in the 7-stranded b-sheet
is too well designed by evolution to be compromised by
any of the SNP substitutions. Actin binding by S1, mod-
ified by SNPs in the main hydrophobic binding site
(F534L and F655S), in Loop 3 (R570K and V572A/D),
Loop 2 (A621V, T631N, A637V, and E643K), the Myo-
pathy loop (R408C, not including the disease implicated
R406W), and the C-loop (R370H, Q371P and P378Q), is
another potential too-robust site. The switch 2 helix,
charged with propagating linear motion from the active
site to the converter domain, suffers seven SNP substi-
tutions and functions while the SH2/SH1 hinge and
lever-arm successfully manage impacts of six and two
SNP substitutions, respectively. Returning to E469Q and
G701R, the functional impact of E469Q (7-stranded b-
sheet) has not been evaluated in vitro, however, other
substitutions at this site were disruptive to muscle myo-
sin function except when the polarity of the R246/E469
salt-bridge was reversed. Then the mutant S1 functioned
near normally. The E469Q substitution seems likely to
disrupt the interaction with R246 thereby altering speci-
f i cr a t e si nt h eA T P a s ec y c l eb u tp o t e n t i a l l yw i t h i n
boundaries that do not overly impact function. The
G701R substitution is difficult to rationalize even in the
too-robust hypothesis. The functional impact of G701R
has likewise not been evaluated in vitro but a glycine
swivel is disrupted by the presence of any side chain
with a b-carbon. How super-fast myosin could function
with G701R needs clarification.
The too-robust hypothesis is often the implicit work-
ing hypothesis for those utilizing site directed mutagen-
esis to study protein mechanisms. It may sometimes be
too optimistic an assumption for interpreting SNPs. The
SNP substitution may affect protein function compen-
sated by redundant functionality outside the affected
protein in the larger physiological system. Different
SNPs will have different applicable hypotheses and the
challenge is to identify the correct one to apply.
We anticipated SNP clustering in a few regions of the
myosin head identifying the expendable components of
the system unrelated to core functionality. This occurred
to some extent within the narrow context of the significant
AHP SNPs. Residues 1-400 in MHC show significant AHP
SNP substitutions at the N-terminus and in the AA280-
360 peptide segments that do not fall into the identified
functional sub-domains. However, residues 401-812 show
a different picture with all but one significant AHP SNP
substitution modifying functional sub-domains. Overview-
ing the total set of substitutions, the S1 SNPs are distribu-
ted spatially over the protein more uniformly than
expected. Figure 8 shows the annotated S1 from Figure 1
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rendering in yellow. Most SNPs locate within, or to the
vicinity of, domains intimately connected to the myosin
core functionality. They do not seem to select any one
structural feature for a diminished role in the core func-
tionality except possibly the 7-stranded b-sheet that
attracted so many SNP substitutions.
The Myopathy loop and the converter domain nearly
escaped modification by SNPs not already disease related.
They each have one SNP substitution not known to be
disease implicated. As suggested by its name, known
mutations in the Myopathy loop accompany heart disease
[27]. SNPs do not appear in the Myopathy loop because
most substitutions cause serious functional deficit. The
same appears to be true for the converter where there are
10 or more heart disease linked mutations. These struc-
t u r e sa r et o o - s e n s i t i v et os u b s t i t u t i o nt ob eat a r g e tf o r
SNPs. The large AHP for the SNP substitution R743Q in
the converter domain (Figure 7) appears to have identi-
fied a unique site in the domain that can be safely modi-
fied. At least for myosin, regions or domains excluded
from SNP substitution may be the most precisely defined.
These high sensitivity regions are anti-targets for SNPs
because they are not functionally robust (i.e. too-sensi-
tive) rather than because they are the only domains
necessary for function.
Conclusions
Single nucleotide polymorphisms of the myosin heavy
chain were mined from the NCBI data base using com-
puter programs written in perl that identified human
nonsynonymous SNP amino acid missense substitutions
for any MHC gene. Twenty-two MHC genes were
searched including muscle and non-muscle myosin iso-
forms. Excluding disease implicated residues and sites
without homology with skeletal myosin 2×, the 71 SNPs
identified were distributed spatially homogeneously over
MHC with 22 falling outside specific functional domains.
The remaining 49 SNPs were spatially related to the 7-
stranded b-sheet mediating active site and actin binding
site communication (17 SNPs), the actin binding peptides
(12 SNPs), switch 2 helix (7 SNPs), SH2/SH1 hinge (6
S N P s ) ,S H 3( 4S N P s ) ,l e v e r - a r m( 2S N P s ) ,a n dc o n v e r t e r
(1 SNP). Two functional elements were almost devoid of
SNPs, the converter domain and the Myopathy loop.
These elements are burdened with an unusually high
number of disease implicated mutations. The SNP substi-
tution sites in MHC suggest they can infiltrate domains
that are engineered by evolution to be “too-robust” to be
disturbed by otherwise intrusive sequence changes, and,
“function-neutral” sites where substitution is immaterial.
Disease implicated mutations and the absence of SNP
substitutions map to regions “too-sensitive” to be modi-
fied because they have not evolved a robust sequence
paradigm for performing their function.
Methods
Automated SNP retrieval
SNP data records were retrieved using a computer pro-
gram written in perl. Perl was chosen because of its text-
parsing and internet capabilities; and because it is widely
available. The basic distribution of perl is available for
use with various operating systems, including Microsoft
Windows, linux/unix, and Macintosh. The first program
(get_snps_flt.pl) uses NCBI eUtils to search for missense
SNPs in the human myosin genes. The results are saved
locally as flat text files then parsed into tables using a sec-
ond perl program (make_table.pl). The get_snps_flt.pl
and make_table.pl programs are listed in the additional
file 1 where there are instructions for their use.
The NCBI SNP database stores individual SNP sub-
missions and assigns them unique identifiers that are
Figure 8 The S1 crystal structure depicted in Figure 1 and with
the heavy chain SNP substitution sites indicated with space
filling models of the unsubstituted side chains. SNP substitutions
locate throughout the myosin S1 heavy chain.
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Page 16 of 20prefixed with ss (submitter sequence). These individual
records are eventually assigned to groups so that all
SNPs that occur at a particular position in a gene are in
the same cluster. Each cluster has a unique numeric
identifier that is prefixed with rs (reference sequence).
Table 2 shows a representative tabular output from
make_table.pl. In every cluster, the reference (or “nor-
mal”) allele is compared to the SNP substituted allele to
determine the missense mutation in the expressible pro-
tein. Up to three SNPs may be reported in a cluster,
corresponding to the three possible non-reference bases.
The residue sequence in Table 2 is the sequence of the
gene product, or myosin isoform, in which the SNP is
detected. Sequence alignment with BLAST positioned
the SNP substitutions on the myosin crystal structure.
Monte Carlo Molecular Dynamics (MCMD) simulation of
myosin dynamics
The dominant kinetic pathway for the actomyosin
ATPase cycle is summarized by solid arrows in Scheme
1.Scheme 1
M, M*, M**, and M^ are intermediates corresponding to
distinct myosin conformations, A is actin, T is ATP, D is
ADP, and P is inorganic phosphate. M* and M** weakly
bind actin while M and M^ strongly bind actin. The bro-
ken arrow (···>) in the bottom row indicates the rate limit-
ing product release step in the absence of actin. Work
production occurs when M** ·D·P weakly binds actin (ver-
tical transition), releases product P with the opening of the
active site “back door” (R246/E469 salt-bridge), and forms
the strong actin bond A·M^·D. The lever-arm rotates to
impel actin ending in the low free energy rigor state A.M.
Cross-bridge repriming begins with ATP binding to A.M
initiating dissociation from actin, ATP hydrolysis, and
reversal of the lever-arm power stroke rotation. The
power stroke, envisioned by comparison of the M** and
M* crystal structures, rotates the lever-arm through ~70
degrees [17,53]. We performed a dynamics simulation for
myosin joining the known M** and M* transient inter-
mediate structures in the Scheme 1pathway using a non-
equilibrium Monte Carlo molecular dynamics (MCMD)
simulation of the M** ® M* conformation trajectory [19].
Table 2 SNPs for smooth muscle myosin MYH11
ID of SNP Cluster Gene Function Base Change Amino Acid Change Peptide Sequence#
a
rs61734198
b MYH11 missense G –>CQ –>H 473
MYH11 missense G –>TQ –>H 473
MYH11 missense G –>CQ –>H 480
MYH11 missense G –>TQ –>H 480
rs16967494 MYH11 missense G –>AA –>T 1234
MYH11 missense G –>AA –>T 1241
rs16967494 MYH11 missense G –>AA –>T 1234
MYH11 missense G –>AA –>T 1241
rs35176378 MYH11 missense A –>GM –>V 1508
MYH11 missense A –>GM –>V 1515
rs35035518 MYH11 missense C –>TS –>L 883
MYH11 missense C –>TS –>L 890
rs34321232 MYH11 missense A –>CK –>Q 1621
MYH11 missense A –>CK –>Q 1628
rs34263860 MYH11 missense G –>AA –>T 1104
MYH11 missense G –>AA –>T 1111
rs16967510 MYH11 missense T –>CV –>A 1289
MYH11 missense T –>CV –>A 1296
rs16967494 MYH11 missense G –>AA –>T 1234
MYH11 missense G –>AA –>T 1241
rs12149651 MYH11 missense C –>AL –>M 1053
MYH11 missense C –>AL –>M 1060
rs7196804 MYH11 missense G –>AV –>M 1310
MYH11 missense G –>AV –>M 1317
rs1801902 MYH11 missense A –>GT –>A 864
MYH11 missense A –>GT –>A 871
aSNPs corresponding to amino acid residues in the tail portion of myosin appear in the output for the automated SNP retrieval program but lie outside the
motor domain of myosin and are not discussed in the text.
bSNP rs61734198 is an example of a two base change (G®Ca n dG ®T) SNP where His substitutes for Gln in both cases. The MYH11 gene product includes
splicing variants with different sequences hence the same SNP has two sequence numbers in the variants that are in this case sm1A (AA473) and sm2B (AA480).
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Page 17 of 20The lever-arm swing conformation change in myosin
occurs on the millisecond time domain and involves
many atoms. We developed the new dynamics simula-
tion strategy because system complexity excludes use of
standard molecular dynamics methods. All conformation
trajectories confirm that during ATPase, an entropy
dominated structural transition in the actin binding
domain of S1 is a free energy barrier ensuring that pro-
duct release is rate limiting in the absence of actin and
prior to the lever-arm swing in agreement with the con-
ventional myosin mechanism. MCMD simulation of the
power stroke indicated that two complementary pep-
tides, designated U50a and U50b (AA145-361 and
AA362-462 peptides), mainly in the 50 kDa actin bind-
ing domain encompass the free energy barrier to pro-
duct release and the anti-barrier, respectively.
Simulation shows that coupling the U50a and U50b
conformation transitions removes the free energy barrier
to product release. The C-loop is a structured surface
loop linking U50a and U50b whose structure would be
perturbed with actin binding. These circumstances sug-
gest that perturbation of the C-loop with actin binding
couples U50a and U50b transitions causing product
release and power stroke initiation.
Homology Modeling
Homology modeling uses a crystal structure template to
constrain a target sequence of unknown structure. The
template is the chicken skeletal myosin S1 (2mys, [17])
and the target sequence is the human fast skeletal MHC
isoform 2× (MYH1) and essential light chain 3 (ELC3).
Homology modeling was done with Modeller 9.4 [96].
All structures shown depict S1 from myosin 2×.
Accurate model building depends on target and
template sequence similarity and alignment. Template
and target sequences for the MHC and ELC are prac-
tically identical (>91% sequence identity) suggesting
Modeller produces a reliable structure [96]. We did
alignment using the NCBI BLAST 2 sequences protocol
http://www.ncbi.nlm.nih.gov/blast/bl2seq/wblast2.cgi.
Unstructured surface loops on myosin were not resolved
in the crystal structures but were added using the appro-
priate Modeller routine. Homology model accuracy was
evaluated using the Discrete Optimized Protein Energy
(DOPE) score as suggested in the Modeller tutorial. The
DOPE score is proportional to potential energy per resi-
due, smoothed over a 15 residue window, and normalized
by the number of restraints acting on each residue. It
indicates problem regions in the homology model when
profiles are compared from target and template
sequences. The DOPE profile showed no unusual pro-
blem regions over the entire peptide.
Visualizations of myosin structures were created in
Visual Molecular Dynamics (VMD) [97] then rendered
in POV-Ray http://www.povray.org/ and output as bit-
map files.
Additional file 1: Instructions for retrieving SNPs. Two perl programs
provide automated retrieval and organization of SNP data from the NCBI
database. Additional file 1 contains the perl programs and instructions
for their use.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2164-11-
172-S1.DOC]
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